Class A Common Stock, $0.01 par value per share
- Symbol
- RPID
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
RPIDNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On March 12, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
RAPID MICRO BIOSYSTEMS, INC. · 8-K · Filed 2026-03-12
EX-99.1 2 ex-991_rpidx12312025.htm EX-99.1 Document Exhibit 99.1 Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance • Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024 • Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024 • Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026 • Samsung Biologics continues to expand Growth Direct deployment across its manufacturing network with a meaningful multi-system order in the first quarter 2026 • For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margin percentage of approximately 20% Lexington, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to fac…
Open exhibit ↗EX-99.2 3 ex-992_rpidx20260312.htm EX-99.2 Document Exhibit 99.2 Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct ® Platform Companies deepen partnership to advance automated, integrated microbiology quality control Lexington, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced a new multi-system order from Samsung Biologics for its Growth Direct platform. This follow-on order builds on the companies’ existing partnership and supports Samsung’s continued expansion of the Growth Direct platform to automate microbial quality control across its manufacturing network. “Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and we’re pleased to strengthen our partnership with this new multi-system order,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Their integrated plant design embeds advanced…
Open exhibit ↗